Intensifying competition in guidewires and related products
First written in FY2017-Q2. 12 of 23 entries say "Restated". Latest entry: FY2025-H1.
No other company in this theme has enough history to compare yet.
- FY2025-H1RestatedAnnual report
「No new business or other risks arose during the current interim consolidated accounting period. In addition, there were no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of intensifying competition in guidewires and other products. - FY2024-Q3RestatedAnnual report
「No new business or other risks arose during the cumulative third quarter of the current consolidated fiscal year. There were also no material changes to the business and other risks described in the securities report for the previous fiscal year.」
The company disclosed that there had been no material changes regarding the risk of intensifying competition in guidewires and other products. - FY2023WorsenedAnnual report
「The company downsized the PI business and shifted sales resources to the gastrointestinal field against a backdrop of intensifying competition, resulting in a substantial decline in sales. Orsiro, the drug-eluting coronary stent that had been a major purchased product, had its exclusive sales agreement terminated early.」
Against a backdrop of intensifying competition, the company downsized the PI business and shifted sales resources, resulting in a 35.4% decline in gastrointestinal/PI sales from the previous fiscal year. - FY2023-Q3WorsenedAnnual report
「The PI business faced an extremely challenging operating environment, as the recovery in case volumes remained slow and reimbursement prices declined substantially with each revision.」
In the PI business, the delayed recovery in case volumes and continued substantial declines in reimbursement prices caused PI sales to fall from ¥2,534 million in the same period of the previous year to ¥1,405 million. - FY2023-Q2WorsenedAnnual report
「The PI business faced an extremely challenging operating environment, as the recovery in case volumes remained slow and reimbursement prices declined substantially with each revision.」
In the PI business, the delayed recovery in case volumes and continued substantial declines in reimbursement prices led to lower sales of guidewires, balloon catheters, and other products. - FY2023-Q1RestatedAnnual report
「The PI business faced an extremely challenging operating environment, as the recovery in case volumes remained slow and selling prices declined following revisions to reimbursement prices.」
In the PI business, the delayed recovery in case volumes, lower unit prices following reimbursement-price revisions, and the competitive environment combined to sustain challenging operating conditions. - FY2022WorsenedAnnual report
「The PI business remained generally challenging, as the recovery in case volumes was delayed overall and competition with other companies intensified.」
In the PI business, the delayed recovery in case volumes and intensifying competition continued to weigh on sales, contributing to an 11.2% decline in overall intervention sales from the previous fiscal year. The company also decided to terminate the Orsiro sales agreement early. - FY2022-Q2RestatedAnnual report
「In the PI business, the recovery in case volumes remained slower than in other treatment areas, and sales of products handled by the company remained generally weak.」
In the PI business, weak sales continued due to the delayed recovery in case volumes, as well as the impact of competing products and the discontinuation of crossing catheter sales. - FY2022-Q1WorsenedAnnual report
「In the PI (percutaneous intervention) business, the number of cases had not recovered as quickly as in other treatment areas. Guidewire and balloon catheter sales declined from the same period of the previous year, partly due to the impact of competing products.」
With the recovery in case volumes delayed and the impact of competing products also weighing, competitive pressure was reflected in lower guidewire and balloon catheter sales. - FY2021-Q3RestatedAnnual report
「Guidewire sales increased from the same period of the previous year as Amati performed steadily and sales volumes grew.」
Despite the impact of competitive pressure and reimbursement-price cuts, Amati sales volumes grew, and guidewire sales increased year on year. - FY2021-Q2RestatedAnnual report
「Guidewire sales increased from the same period of the previous year as Amati performed steadily and sales volumes grew.」
Despite continued competitive pressure, Amati sales volumes grew, and guidewire sales increased year on year. - FY2020MitigatedAnnual report
「Sales of existing balloon catheters declined from the previous fiscal year due to the impact of competing products, while sales volumes of the new ignis product, launched in October 2019, grew steadily. Guidewire sales also increased from the previous fiscal year as Amati, known for its high maneuverability, gained strong recognition in clinical practice.」
Existing balloon catheter sales continued to decline due to competing products, but sales volumes of the new ignis product grew, and guidewire sales increased as Amati gained recognition. - FY2020-Q3WorsenedAnnual report
「Among other products, crossing catheter sales declined from the same period of the previous year as competition intensified.」
Intensifying competition was explicitly identified, and its impact continued to appear as lower crossing catheter sales. Meanwhile, guidewire sales increased due to Amati's contribution. - FY2020-Q2RestatedAnnual report
「Balloon catheter sales declined from the same period of the previous year due to the impact of competing products. In contrast, guidewire sales increased from the same period of the previous year as Amati, which began full-scale sales in October 2018, gained recognition for its high maneuverability and safety.」
While balloon catheter and GuideLiner sales continued to decline due to the impact of competing products, guidewire sales increased as Amati gained recognition. - FY2020-Q1RestatedAnnual report
「Balloon catheter sales declined from the same period of the previous year due to the impact of competing products. In contrast, guidewire sales increased as Amati, which began full-scale sales in October 2018, gained recognition for its high maneuverability and safety amid a challenging competitive environment.」
While balloon catheter and GuideLiner sales continued to decline due to the impact of competing products, increased recognition and sales of Amati partly offset the decline in guidewire sales. - FY2019MitigatedAnnual report
「Guidewire sales increased from the previous fiscal year, despite a challenging competitive environment, supported by Amati, which began full-scale sales in October 2018.」
The competitive environment remained challenging, but full-scale sales of the new Amati product increased guidewire sales from the previous fiscal year, providing some evidence of progress in addressing competitive and pricing pressure. - FY2019-Q3RestatedAnnual report
「Among other products, sales of the atrial septal defect occluder Figulla FlexⅡ and the crossing catheter Guideliner declined from the same period of the previous year due to the impact of competing products.」
Sales of Figulla FlexⅡ and Guideliner continued to decline due to the impact of competing products. - FY2019-Q2RestatedAnnual report
「Among other products, sales of the atrial septal defect occluder Figulla FlexⅡ and the crossing catheter Guideliner also declined from the same period of the previous year, with Guideliner sales affected by competing products.」
Guideliner sales continued to decline due to the impact of competing products. Balloon catheter and guidewire sales also declined as a result of official price cuts. - FY2019-Q1WorsenedAnnual report
「Sales of balloon catheters and guidewires declined from the same period of the previous year, due to substantial reimbursement-price cuts and the impact of competing products.」
In guidewires and other products, the impact of competing products and substantial reimbursement-price cuts again manifested as lower sales, reflecting competitive and pricing pressure. - FY2018MitigatedAnnual report
「Guidewire sales volumes rose only slightly from the previous fiscal year amid a challenging competitive environment.」
The challenging competitive environment continued, but sales volumes recovered from a year-on-year decline to a slight increase. The increase was limited. - FY2017RestatedAnnual report
「Guidewire sales volumes declined from the previous fiscal year amid a challenging competitive environment.」
Intensifying competition and lower guidewire sales volumes were also confirmed for the full fiscal year. - FY2017-Q3RestatedAnnual report
「Guidewire sales also declined amid a challenging competitive environment, due to lower sales volumes than in the same period of the previous year and the impact of reimbursement-price cuts.」
The challenging competitive environment for guidewires, lower sales volumes, and reimbursement-price cuts continued to weigh on sales. - FY2017-Q2First statedAnnual report
「The guidewire business faced a challenging competitive environment, and sales declined due to lower sales volumes than in the same period of the previous year as well as the impact of reimbursement-price cuts.」
The challenging competitive environment for guidewires is reflected in lower sales volumes and net sales.